Literature DB >> 20733282

Immunomodulatory effects of macrolide antibiotics - part 2: advantages and disadvantages of long-term, low-dose macrolide therapy.

J Altenburg1, C S de Graaff, T S van der Werf, W G Boersma.   

Abstract

The available evidence for long-term, low-dose treatment with 14- and 15-membered ring macrolides in non-cystic fibrosis (CF) bronchiectasis, COPD, chronic sinusitis, and asthma is reviewed with special attention to possible adverse effects and the emergence of resistance during long-term macrolide treatment. Macrolide maintenance therapy has been proven to be of benefit in diffuse panbronchiolitis and CF, presumably due to an anti-inflammatory mechanism of action in addition to its direct antimicrobial effect. Solid evidence to justify this treatment regimen for non-CF bronchiectasis, asthma, or sinusitis is still lacking, although a beneficial effect of long-term macrolide therapy has been found in small clinical trials on these subjects. Data from randomized trials of long-term macrolide treatment in COPD are conflicting. A sufficiently long duration of treatment and the careful selection of patients appears to be crucial. Aside from its beneficial effects, possible side effects of macrolide treatment should be taken into account, the most important of these being gastrointestinal upset and cardiac arrhythmias. Development of macrolide resistance among respiratory pathogens is very common during long-term macrolide treatment. Whether this finding is clinically significant is a matter of debate.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20733282     DOI: 10.1159/000320320

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  19 in total

Review 1.  Antibacterial and immunomodulatory properties of azithromycin treatment implications for periodontitis.

Authors:  P M Bartold; A H du Bois; S Gannon; D R Haynes; R S Hirsch
Journal:  Inflammopharmacology       Date:  2013-02-28       Impact factor: 4.473

Review 2.  Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.

Authors:  P Zarogoulidis; N Papanas; I Kioumis; E Chatzaki; E Maltezos; K Zarogoulidis
Journal:  Eur J Clin Pharmacol       Date:  2011-11-22       Impact factor: 2.953

3.  Low-dose clarithromycin therapy modulates Th17 response in non-cystic fibrosis bronchiectasis patients.

Authors:  Evangelia Fouka; Eleftheria Lamprianidou; Konstantinos Arvanitidis; Eirini Filidou; George Kolios; Paraskevi Miltiades; Emmanouil Paraskakis; Antonios Antoniadis; Ioannis Kotsianidis; Demosthenes Bouros
Journal:  Lung       Date:  2014-07-14       Impact factor: 2.584

4.  TH17 cells and corticosteroid insensitivity in severe asthma.

Authors:  Yan Xie; Peter W Abel; Thomas B Casale; Yaping Tu
Journal:  J Allergy Clin Immunol       Date:  2021-12-23       Impact factor: 10.793

5.  Bronchiectasis.

Authors:  Changhwan Kim; Dong-Gyu Kim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2012-11-30

6.  Optimal management of severe/refractory asthma.

Authors:  Smita Pakhale; Sunita Mulpuru; Matthew Boyd
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2011-08-31

Review 7.  Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics.

Authors:  Helen C Steel; Annette J Theron; Riana Cockeran; Ronald Anderson; Charles Feldman
Journal:  Mediators Inflamm       Date:  2012-06-21       Impact factor: 4.711

8.  Clinical differences between influenza A (H1N1) virus and respiratory infection between the two waves in 2009 and 2010.

Authors:  Paul Zarogoulidis; Dimitrios Glaros; Ioannis Kioumis; Eirini Terzi; Konstantinos Porpodis; Anastasios Tsiotsios; Anastasios Kallianos; Georgia Trakada; Nikolaos Machairiotis; Aikaterini Stylianaki; Antonis Sakas; Ageliki Rapti; Nikolaos Courcoutsakis; Theodoros C Constantinidis; Efstartios Maltezos; Konstantinos Zarogoulidis
Journal:  Int J Gen Med       Date:  2012-08-13

9.  Minocycline down-regulates topical mucosal inflammation during the application of microbicide candidates.

Authors:  Liangzhu Li; Yinyin Ben; Zhaoqin Zhu; Weihua Li; Jianqing Xu; Xiaoyan Zhang
Journal:  PLoS One       Date:  2012-08-14       Impact factor: 3.240

10.  Clinical case of botryomycome fulminant at the center of diagnostic and treatment of tuberculosis of Baleng (West - Cameroon).

Authors:  Michel Noubom; Bruno Kenfack; Jean Hubert Donfack; Fabrice Djouma Nembot; Zacharie Sando
Journal:  Pan Afr Med J       Date:  2013-04-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.